Practical considerations for the implementation of adaptive designs for oncology Phase I dose-finding trials [0.03%]
肿瘤学一期剂量寻找试验的自适应设计实施中的实际考虑因素
Lai Wei,Xueliang Pan,Soledad Fernandez
Lai Wei
The traditional 3 + 3 design continues to be commonly used for Phase I dose-finding oncology trials, despite increasing criticisms and development of innovative methods. Unfortunately, it is a challenge to convince principal investigators t...
Perlecan-targeted nanoparticles for drug delivery to triple-negative breast cancer [0.03%]
针对三阴性乳腺癌药物递送的硫酸肝素蛋白多糖纳米颗粒靶向疗法
Vidhi Khanna,Stephen Kalscheuer,Ameya Kirtane et al.
Vidhi Khanna et al.
Aim: We previously developed two antibodies that bind to a cell surface protein, perlecan, overexpressed in triple-negative breast cancer (TNBC). The goal of this study was to investigate these antibodies as targeting lig...